Trial · NCT01289821
Adverse events110
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 110
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 7 | 53 | 12 |
| other | Hoarseness | Respiratory, thoracic and mediastinal disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 7 | 53 | 11 |
| other | Sore throat | Respiratory, thoracic and mediastinal disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 4 | 53 | 4 |
| other | Voice alteration | Respiratory, thoracic and mediastinal disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 12 | 53 | 29 |
| other | Hematuria | Renal and urinary disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 4 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 15 | 53 | 15 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 6 |
| other | Hyperhidrosis | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 5 |
| other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 6 | 53 | 7 |
| other | Palmar-plantar erythrodysesthesia syndrome | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 19 | 53 | 47 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 4 | 53 | 5 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 5 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 6 | 53 | 10 |
| other | Flushing | Vascular disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 8 |
| other | Hypotension | Vascular disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 5 | 53 | 5 |
| other | Hypertension | Vascular disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 30 | 53 | 134 |
| other | Phlebitis | Vascular disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| other | Thromboembolic event | Vascular disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 3 | 53 | 3 |
| serious | Febrile neutropenia | Blood and lymphatic system disorders | Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 1 | 53 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01289821/events?page=4